EP1380576A1 — Novel 1h-indazole compound
Assigned to Eisai R&D Management Co Ltd · Expires 2004-01-14 · 22y expired
What this patent protects
The present invention provides a novel 1 H -indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R 1 is a C 6 -C 14 aromatic cyclic hydrocarbon…
USPTO Abstract
The present invention provides a novel 1 H -indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R 1 is a C 6 -C 14 aromatic cyclic hydrocarbon group etc.; R 2 , R 4 and R 5 each independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C 1 -C 6 alkylene group etc.; X is a single bond, or a group represented by -CO-NH- or -NH-CO-, etc.; and Y is a C 3 -C 8 cycloalkyl group, a C 6 -C 14 aromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.
Drugs covered by this patent
- Kalydeco (IVACAFTOR) · Vertex Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.